Sotac Pharmaceuticals Ltd
Incorporated in 2015, Co. is in the business of manufacturing pharmaceutical products for different marketers on a loan license or contract manufacturing basis[1]
- Market Cap ₹ 134 Cr.
- Current Price ₹ 121
- High / Low ₹ 155 / 97.0
- Stock P/E 36.0
- Book Value ₹ 38.7
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 3.13 times its book value
- Debtor days have increased from 57.2 to 70.4 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2023 | TTM | |
---|---|---|---|---|
28.60 | 48.84 | 77.48 | 95.46 | |
26.73 | 47.38 | 70.17 | 85.70 | |
Operating Profit | 1.87 | 1.46 | 7.31 | 9.76 |
OPM % | 6.54% | 2.99% | 9.43% | 10.22% |
0.22 | 0.11 | 0.93 | 0.80 | |
Interest | 0.33 | 1.03 | 2.04 | 2.76 |
Depreciation | 1.40 | 2.59 | 2.28 | 2.82 |
Profit before tax | 0.36 | -2.05 | 3.92 | 4.98 |
Tax % | 75.00% | -15.12% | 41.84% | |
0.09 | -2.37 | 2.29 | 3.57 | |
EPS in Rs | 0.39 | -10.30 | 2.84 | 3.58 |
Dividend Payout % | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 39% |
TTM: | % |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 190% |
TTM: | % |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|
Equity Capital | 2.30 | 2.30 | 8.05 | 11.05 |
Reserves | 0.76 | 0.19 | 11.41 | 31.68 |
13.44 | 17.13 | 22.04 | 21.02 | |
13.89 | 15.08 | 32.14 | 35.41 | |
Total Liabilities | 30.39 | 34.70 | 73.64 | 99.16 |
15.99 | 16.56 | 25.92 | 34.80 | |
CWIP | 0.00 | 0.00 | 0.04 | 1.60 |
Investments | 0.16 | 0.30 | 0.00 | 0.00 |
14.24 | 17.84 | 47.68 | 62.76 | |
Total Assets | 30.39 | 34.70 | 73.64 | 99.16 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2023 | |
---|---|---|---|
0.06 | -0.31 | 8.14 | |
-11.75 | -3.23 | -11.67 | |
11.40 | 3.38 | 13.14 | |
Net Cash Flow | -0.29 | -0.16 | 9.61 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2023 | |
---|---|---|---|
Debtor Days | 88.83 | 43.94 | 70.38 |
Inventory Days | 39.53 | 44.76 | 86.93 |
Days Payable | 194.09 | 120.65 | 161.82 |
Cash Conversion Cycle | -65.73 | -31.95 | -4.51 |
Working Capital Days | 14.29 | 14.95 | 27.89 |
ROCE % | -5.39% |
Business Verticals
A) Manufacturing of Non-Beta-Lactam Medicines and Formulations [1]
It manufactures Non-Beta-Lactam (general) tablets, Non-Beta-Lactam (general) capsules, oral liquid, dry syrup, and external preparations such as Ointment, Lotion, and cream and caters to 162 corporate clients on a loan license and/or contract manufacturing basis